en · de · es · pt
tb-500-notes.peptides6088.com › Faq › Identity And Reported Background — Research Overview

Identity And Reported Background — Research Overview

By Editorial Desk · published 2026-02-17 · last reviewed 2026-03-31 · Faq

This is a working overview of research peptide, written for readers who want more than a one-paragraph summary but less than a textbook.

Reviewed 2026-03-31. Anything still debated is marked as such rather than presented as settled.

Identity and Reported Background

Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.

TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.

Thymosin Beta-4 Fragment Identity

No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.

TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.

Tb-500 at a glance

PropertyValueNotes
Reported sequenceAc-LKKTETQDescribed in most listings as the actin-binding region of thymosin beta-4
Reported molecular weightApproximately 889 DaValue shifts with the stated sequence; compare against the certificate of analysis
Parent protein length43 amino acidsThymosin beta-4; the fragment covers only a small part of it
Common synonymsTB4 fragment; thymosin beta-4 fragmentTrade-style names rather than formal nomenclature
Formal monographsNot establishedLabeling conventions differ by supplier and region

Handling, Storage and Quality Checks

Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.

Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.

Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.

Related pages on this site

TB-500 Background and Identity

The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.

Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.

TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.

Storage, Handling, and Analytical Checks

The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.

Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.

TB-500 Identity and Naming Background

Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.

TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.

Further detail

== Ultrapure water standards == A number of organizations and groups develop and publish standards associated with the production of UPW. For microelectronics and power, they include Semiconductor Equipment and Materials International (SEMI) (microelectronics and photovoltaic), American Society for Testing and Materials International (ASTM International) (semiconductor, power), Electric Power Research Institute (EPRI) (power), American Society of Mechanical Engineers (ASME) (power), and International Association for the Properties of Water and Steam (IAPWS) (power). Pharmaceutical plants follow water quality standards as developed by pharmacopeias, of which three examples are the United States Pharmacopeia, European Pharmacopeia, and Japanese Pharmacopeia.

=== Partition coefficient === Study of the solubility data shows that bronopol has a high affinity for polar rather than non-polar environments. In two-phase systems, bronopol partitions preferentially into the polar (usually aqueous) phase.

=== Telemedicine integration === The rapid expansion of telemedicine during COVID-19 created natural synergies with DTC testing, enabling remote consultation for test result interpretation and follow-up care.

== Regulation and policy == In the United States, there are approximately 1,500 methadone clinics that are federally certified opioid treatment programs. There are generally two types of methadone clinics, public and private. The public clinics are generally cheaper to attend. However, there is usually a waiting list due to limited funding. The private clinics are more expensive to attend but usually have either a short or no waiting list. In many parts of the United States, methadone clinics are few and far between, which presents problems for addicts seeking methadone treatment who live far from a clinic. All methadone clinics must register as an accredited opioid treatment program with the Substance Abuse and Mental Health Service Administration and renew yearly or every three years based on the accreditation time frame awarded. Additionally, methadone clinics must register with the Drug Enforcement Administration before methadone can be dispensed. While not restricted to adults, this treatment method is generally not considered for people under the age of 18. Methadone clinics in the United States operate under strict regulations by state and federal laws. Before entering treatment, a patient must be given adequate information to provide informed consent about starting treatment. This information includes reasons for treatment and recommendations, the side effects and risks of treatment, and rules that must be followed to receive methadone treatment.

=== Elimination === Testosterone and its metabolites are eliminated in urine. It is excreted mainly as androsterone glucuronide and etiocholanolone glucuronide. It is also excreted to a small extent as other conjugates such as testosterone glucuronide (1%), testosterone sulfate (0.03%), and androstanediol glucuronides. Only a very small amount of testosterone (less than 0.01%) is found unchanged in the urine.

Sources: en.wikipedia.org

Supporting material

=== Swine Flu Outbreak === In 2009, Hetero established Hetero Biopharma, a dedicated R&D unit, and set up a biological manufacturing unit in Hyderabad and quickly became a manufacturer of affordable biosimilars. In the same year, Hetero garnered widespread attention for its public health emergency response capabilities during the Swine Flu outbreak. As various health organizations and government agencies were piling up stocks of Oseltamivir as precautionary measures, Hetero supplied generic Oseltamivir under its brand name Fluvir. Hetero delivered 10 million doses of Oseltamivir to the Indian government in 2009, and shipped about 80 million doses to over 60 countries.Hetero received its second order from Indian government to supply another 10 million doses of Oseltamivir later in 2009. 2014-2019 In 2014, Hetero launched the blockbuster drug Sofosbuvir, a direct-acting antiviral used for the treatment of Hepatitis C, with approval from Gilead Sciences. The drug was marketed and sold in 90 countries, including India, Asia Pacific, Sub-Saharan Africa and other least developed countries, making it accessible at a substantially lower cost to patients. In 2015, Hetero took a step further in Hep C care by becoming the first company in India to launch the fixed-dose combination of Ledipasvir+ Sofosbuvir, used in the treatment of chronic hepatitis genotype 1 in both treatment –naïve and treatment experienced patients.

=== Property nationalized === In 1974, the Peruvian government nationalized properties in Peru owned by the company. Harold Logan, Grace's executive vice president, stated the company would join in governmental-level talks over compensation of expropriated American concerns. The loss of Grace's properties in Peru began in 1969 when 25,000 acres of sugarcane plantations were taken over in agrarian reform. The sugar lands were at Paramonga, 110 miles north of Lima, and at Cartavio, near Trujillo, 200 miles farther up the coast. Grace retained small mining operations producing copper, tin, and silver, in southern Peru, about 100 miles north of Juliaca. Jose E. Flores, head of W. R. Grace S.A. Peru, closed the mining operations for Grace in Latin America when the government of Peru nationalized the remaining interests.

They were fought as both irregular warfare and conventional warfare. Some historians claim they began as localized civil wars that spread as secessionist wars for general independence. The new national boundaries followed the colonial provinces and formed the basis of contemporary Hispanic America. Cuba and Puerto Rico remained under Spanish rule until the 1898 Spanish–American War. The Spanish Empire dissolved in the region and new states emerged. The new republics abandoned the Inquisition and noble titles, but slavery was not immediately abolished, and total abolition came only in the 1850s in most countries. Criollos and mestizos replaced Spanish-born officials in most political offices, and Criollos stayed at the top of a social structure that kept traditional features culturally, if not legally. For almost a century, conservatives and liberals fought to reverse or deepen these changes. Spaniards were also subject to forced displacement, during the war and later through expulsion laws meant to consolidate independence. The wars followed the Haitian Revolution (1791–1804) and unfolded alongside Brazil's own path to independence. Spanish America and Brazil shared a trigger: Napoleon's invasion of Iberia, which in 1807 forced the Portuguese royal family to flee to Brazil. More broadly, they drew on the Enlightenment ideas of popular sovereignty behind the Atlantic Revolutions, including the American and French ones. The more direct cause was the crisis within Spain, which ended with new independent states in the post-Napoleonic world.

In April 2022, the FDA released draft guidance on its policy regarding products labeled as dietary supplements that contain N-acetyl-L-cysteine. Amazon subsequently re-listed NAC products as of August 2022.

== Adverse effects == Adverse effects of flunitrazepam include dependency, both physical and psychological; reduced sleep quality resulting in somnolence; and overdose, resulting in excessive sedation, impairment of balance and speech, respiratory depression or coma, and possibly death. Because of the latter, flunitrazepam is commonly used in suicide among the elderly. When used in late pregnancy, it might cause hypotonia of the fetus.

Sources: en.wikipedia.org

Supporting material

== Examples == The following examples calculate the nominal and monoisotopic masses of a molecule of nitrogen (N2) and ethylene (C2H4). For these elements the most abundant isotopes are 12C, 1H, and 14N.

Nicergoline is an ergot alkaloid derivative that acts as a potent and selective α1A-adrenergic receptor antagonist. The IC50 of nicergoline in vitro has been reported to be 0.2 nM. The primary action of nicergoline is to increase arterial blood flow by vasodilation. Furthermore, it is known that nicergoline inhibits platelet aggregation. Studies have shown that nicergoline also increases nerve growth factor in the aged brain. In addition to the α1A-adrenergic receptor, nicergoline is an antagonist of the serotonin 5-HT1A receptor (IC50 = 6 nM) and shows moderate affinity for serotonin 5-HT2 and α2-adrenergic receptors and low affinity for the dopamine D1 and D2 and muscarinic acetylcholine M1 and M2 receptors.

12 July – NASA releases the first suite of images from the now fully operational James Webb Space Telescope, a day after releasing the Webb's First Deep Field, the image of early universe with the highest resolution. On 14 July, NASA presents images of Jupiter and related areas captured, for the first time, and including infrared views, by the telescope. On 19 July, scientists report what could be the earliest and most distant galaxy ever discovered, GLASS-z12. 13 July The discovery of fast radio burst FRB 20191221A with an unusually long duration of three seconds is reported. A study affirms (see 7 March) that critical slowing down indicators suggest that tropical, arid and temperate forests are substantially losing resilience. On 4 July, Brazil's INPE reports that the country's regions of the Amazon rainforest have been deforested by a record amount in the first half of 2022. A study shows that blood cells' loss of the Y chromosome in a subset of cells, reportedly affecting at least 40% of 70 years-old men to some degree, contributes to fibrosis, heart risks, and mortality in a causal way. Researchers report the development of semitransparent solar cells that are as large as windows, after team members achieved record efficiency with high transparency in 2020. On 4 July, researchers report the fabrication of solar cells with a record average visible transparency of 79%, being nearly invisible.

== Early life and education == Born in Aarberg, Switzerland, Wüthrich was educated in chemistry, physics, and mathematics at the University of Bern before pursuing his PhD supervised by Silvio Fallab at the University of Basel, awarded in 1964.

Sources: en.wikipedia.org

Frequently asked questions

What is TB-500 made of?

Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.

Is TB-500 the same as thymosin beta-4?

No. Thymosin beta-4 is a protein of 43 amino acids, while TB-500 is described as a short fragment of it. The two differ in size, structure, and the range of interactions each can support.

Why do product descriptions differ between suppliers?

Naming for research peptides is not centrally coordinated, so vendors set their own labels and specifications. Differences in stated sequence, molecular weight, or purity documentation usually trace back to those independent labeling choices.

Is TB-500 the same as thymosin beta-4?

Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.

Network